The HGDH Study Group includes Drs Jeffrey A. Lieberman, Diana O. Perkins, Robert Hamer, Department of Psychiatry, University of North Carolina School of Medicine, North Carolina; Dr Charles B. Nemeroff, Department of Psychiatry, Emory University School of Medicine, Georgia; Drs Bruce Cohen, Franca Centhorrino, McLean Hospital, Harvard Medical School, Massachusetts; Drs Gary Tollefson,Todd Sanger, Mauricio Tohen, Lilly Research Laboratories and McLean Hospital, Belmont, Massachusetts; Dr Joseph P. McEvoy, John Umstead Hospital, North Carolina; Dr John Kuldau, Department of Psychiatry, University of Florida, Florida; Dr Alan I. Green, Dartmouth Medical School, New Hampshire; Dr Anthony J. Rothschild, Jayendra K. Patel, Department of Psychiatry, University of Massachusetts Medical Center, Massachusetts; Dr Raquel E. Gur, Department of Psychiatry, University of Pennsylvania Medical Center, Pennsylvania, USA; Drs Robert B. Zipursky, Zafiris J. Daskulakis, Department of Psychiatry,University of Toronto Faculty of Medicine, Canada; Dr Stephen M. Strakowski, Department of Psychiatry, University of Cincinnati, Ohio; Dr Ira Glick, Department of Psychiatry, Stanford University School of Medicine, California; Dr John De Quardo, Department of Psychiatry,University of Michigan Medical Center, Missouri, USA; Professor Dr R. S. Kahn, University Hospital Utrecht, The Netherlands; Professor Tonmoy Sharma, Clinical Neuroscience Research Centre, Kent; Professor Robin Murray, Institute of Psychiatry, London,UK.
Allison, D. B. & Casey, D. E. (2001) Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry, 62 (suppl. 7), 22–31.
Allison, D. B., Mentore, J. L., Heo, M., et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156, 1686–1696.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.
Beasley, C. M. Jr, Hamilton, S. H., Crawford, A. M., et al (1997) Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology, 7, 125–137.
Blin, O. & Micallef, J. (2001) Antipsychotic-associated weight gain and clinical outcome parameters. Journal of Clinical Psychiatry, 62 (suppl. 7), 11–21.
Ganguli, R., Brar, J. S. & Ayrton, Z. (2001) Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophrenia Research, 49, 261–267.
Gupta, S., Droney, T., Al-Samarrai, S., et al (1999) Olanzapine: weight gain and therapeutic efficacy. Journal of Clinical Psychopharmacology, 19, 273–275.
Kay, S. R., Opler, L. A. & Fiszbein, A. (1992) Positive and Negative Syndrome Scale (PANSS): Manual. New York: Multi-Health Systems, Inc.
Kinon, B. J., Basson, B. R., Gilmore, J. A., et al (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry, 62, 92–100.
Lieberman, J. A., Tollefson, G., Tohen, M. D., et al (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry, 160, 1396–1404.
Lindenmayer, J. P., Czobor, P., Volavka, J., et al (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry, 160, 290–296.
Newcomer, J. W., Haupt, D. W., Fucetola, R., et al (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry, 59, 337–345.
Sachs, G. S. & Guille, C. (1999) Weight gain associated with use of psychotropic medications. Journal of Clinical Psychiatry, 60 (suppl. 21), 16–19.
Sheitman, B. B., Bird, P. M., Binz, W., et al (1999) Olanzapine-induced elevation of plasma triglyceride levels. American Journal of Psychiatry, 156, 1471–1472.
Tollefson, G. D., Beasley, C. M., Tamura, R. N., et al (1997) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine and haloperidol. American Journal of Psychiatry, 154, 1248–1254.
Wirshing, D. A. (2001) Adverse effects of atypical antipsychotics. Journal of Clinical Psychiatry, 62 (suppl. 21), 7–10.